Known targets — ChEMBL curated mechanism
GABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQSCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9A
The experimentally established mechanism targets of Phenobarbital. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SCN1A known ✓ | P35498 | 1/20 | 0.40 |
| ▸ | SCN4A known ✓ | P35499 | 1/20 | 0.40 |
| ▸ | SCN5A known ✓ | Q14524 | 1/20 | 0.40 |
| ▸ | SCN2A known ✓ | Q99250 | 1/20 | 0.40 |
| ▸ | SCN3A known ✓ | Q9NY46 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.87 |
| ▸ | MEN1 | O00255 | 1/20 | 0.87 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.87 |
| ▸ | POLB | P06746 | 1/20 | 0.87 |
| ▸ | TSHR | P16473 | 1/20 | 0.87 |
| ▸ | APEX1 | P27695 | 1/20 | 0.87 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.87 |
| ▸ | MMP2 | P08253 | 6/20 | 0.67 |
| ▸ | MMP9 | P14780 | 6/20 | 0.67 |
| ▸ | MMP3 | P08254 | 3/20 | 0.67 |
| ▸ | LMNA | P02545 | 4/20 | 0.53 |
| ▸ | MMP13 | P45452 | 2/20 | 0.49 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.48 |
| ▸ | MMP8 | P22894 | 1/20 | 0.44 |
| ▸ | CACNA1F | O60840 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Primidone SCHEMBL34221 | 0.93 | KMT2A (1.00) | KMT2AMEN1CYP1A2POLBTSHR | |
| Phenobarbital SCHEMBL19991483 | 0.90 | MMP2 (0.75) | KMT2AMEN1CYP1A2POLBTSHR | |
| Phenobarbital SCHEMBL2592325 | 0.90 | MMP2 (0.80) | KMT2AMEN1CYP1A2POLBTSHR | |
| Phenobarbital SCHEMBL16583 | 0.90 | MMP2 (0.80) | KMT2AMEN1CYP1A2POLBTSHR | |
| Phenobarbital SCHEMBL18825042 | 0.90 | MMP2 (0.80) | KMT2AMEN1CYP1A2POLBTSHR | |
| Phenobarbital SCHEMBL28099657 | 0.90 | MMP2 (0.80) | KMT2AMEN1CYP1A2POLBTSHR | |
| Phenobarbital SCHEMBL2120028 | 0.88 | MMP2 (0.77) | KMT2AMEN1CYP1A2POLBTSHR | |
| Phenobarbital SCHEMBL1322895 | 0.88 | MMP2 (0.77) | KMT2AMEN1CYP1A2POLBTSHR | |
| Phenobarbital SCHEMBL22032658 | 0.88 | MMP2 (0.77) | KMT2AMEN1CYP1A2POLBTSHR | |
| Phenobarbital SCHEMBL6807467 | 0.88 | MMP2 (0.77) | KMT2AMEN1CYP1A2POLBTSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2699572-A1 | HETEROCYCLIC COMPOUNDS AS KINASE INHIBITORS | Origenis GmbH (DE) | 2014-02-26 | — | — | EP | disclosed |
| EP-2699579-A1 | PYRAZOLO [4, 3-D]PYRIMIDINES USEFUL AS KINASE INHIBITORS | Origenis GmbH (DE) | 2014-02-26 | — | — | EP | disclosed |
| US-8478419-B2 | Modulation and analysis of cerebral perfusion in epilepsy and other neurological disorders | NEUROPACE, INC. (US) | 2013-07-02 | — | — | US | disclosed |
| WO-2012143144-A1 | PYRAZOLO [4, 3-D] PYRIMIDINES USEFUL AS KINASE INHIBITORS | ORIGENIS GMBH (DE) | 2012-10-26 | — | — | WO | disclosed |
| WO-2012143143-A1 | HETEROCYCLIC COMPOUNDS AS KINASE INHIBITORS | ORIGENIS GMBH (DE) | 2012-10-26 | — | — | WO | disclosed |
| US-7892182-B2 | Modulation and analysis of cerebral perfusion in epilepsy and other neurological disorders | NEUROPACE, INC. (US) | 2011-02-22 | — | — | US | disclosed |
| US-20090069863-A1 | MODULATION AND ANALYSIS OF CEREBRAL PERFUSION IN EPILEPSY AND OTHER NEUROLOGICAL DISORDERS | NEUROPACE, INC. (US) | 2009-03-12 | — | — | US | disclosed |
| US-20080046026-A1 | MODULATION AND ANALYSIS OF CEREBRAL PERFUSION IN EPILEPSY AND OTHER NEUROLOGICAL DISORDERS | NEUROPACE, INC. (US) | 2008-02-21 | — | — | US | disclosed |
| EP-1553952-A1 | USE OF DIHYDROIMIDAZOLONES FOR THE TREATMENT OF EPILEPSY IN DOGS | BOEHRINGER INGELHEIM VETMEDICA GMBH (DE) | 2005-07-20 | — | — | EP | disclosed |
| WO-2004032938-A1 | USE OF DIHYDROIMIDAZOLONES FOR THE TREATMENT OF EPILEPSY IN DOGS | BOEHRINGER INGELHEIM VETMEDICA GMBH (DE) | 2004-04-22 | — | — | WO | disclosed |